Drug Trial Radar · NCT06805812
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
Last checked: Nov 19, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,500
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
Dec 31, 2030
Study completion Dec 31, 2040
Sponsor
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Institute of Oncology, Italy; Humanitas Research Hospital IRCCS, Rozzano-Milan; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia; OSPEDALE ASST CREMONA; IOV Oncologico Veneto Padova; ASST Fatebenefratelli Sacco; IRCCS Fondazione Salvatore Maugeri, Pavia, Italy; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola; Azienda Ospedaliero-Universitaria di Modena; Azienda Ospedaliero Universitaria Maggiore della Carita; A.O.U. Federico II, Napoli; San Raffaele University Hospital, Italy; Centro di Riferimento Oncologico - Aviano; Azienda Socio-Sanitaria Territoriale Lariana; Azienda ULSS 3 Serenissima, Ospedale di Mirano; Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma; Fondazione IRCCS Policlinico San Matteo di Pavia; IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Azienda Ospedaliero-Universitaria Careggi; Humanitas, Istituto Clinico Catanese; Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale; Fondazione Policlinico Universitario Campus Bio-Medico; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- First posted
- Feb 3, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PALMARES-2 is a retrospective/prospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+/HER2- aBC patients treated with first-line CDK4/6i plus ET. The present study has the objective to collect data coming from different sources, i.e. RWD, medical images and biological samples, from patients treated with CDK4/6i as first-line of therapy for HR+/HER2- aBC. In consideration of the complexity of data collected and different objectives of the study, this master protocol foresees different sub-studies, which encompasses different methodologies for data collection, data extraction and analyses.
Conditions
- Breast Adenocarcinoma
- Breast Cancer Stage IV
- Breast Cancer, Metastatic
- Breast Carcinoma
- Breast Diseases
- Breast Neoplasms
- Breast Neoplasms, Male
- Breast Cancer
- Breast Cancer With Metastatic Bone Disease
- Breast Cancers
- Breast Neoplasm
- Breast Tumors
- HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
- HR+ Advanced or Metastatic Breast Cancer
- HR+/HER2- Breast Cancer
- HRpos Breast Neoplasms
- HR-positive, HER2-negative Advanced Breast Cancer
- HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
- HR-positive Breast Cancer
- Hormone Receptor-Positive Breast Cancer
- Hormone Receptor Positive Breast Adenocarcinoma
- Hormone Receptor Positive Breast Carcinoma
- Hormone Receptor Positive Breast Neoplasms
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Hormone Receptor Positive Metastatic Breast Cancer
- Hormone Receptor Positive, HER2 Negative Breast Cancer
- Hormone Receptor Negative Breast Cancer
- Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
- Hormone Receptor Positive, HER2-negative Neoplasms
- Hormone Receptor Positive, HER2-low Neoplasms
- Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
- Hormone Receptor (HR)-Positive Breast Cancer
- Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- Palbociclib
- Ribociclib
- Abemaciclib
- CDK4/6 Inhibitor
- CDK4/6 Inhibitors
Interventions
PalbociclibDrug
Administered in combination with endocrine therapy
RibociclibDrug
Administered in combination with endocrine therapy
AbemaciclibDrug
Administered in combination with endocrine therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From the first-line treatment start to date of any-cause death or last follow up, up to 120 months
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Centro di Riferimento Oncologico IRCCS
Aviano, Italy · Recruiting
Azienda Socio Sanitaria Territoriale degli Spedali Civili
Brescia, Italy · Recruiting
Humanitas Istituto Clinico Catanese
Catania, Italy · Recruiting
ASST Lariana - Ospedale Sant'Anna
Como, Italy · Recruiting
ASST Ospedale Maggiore
Cremona, Italy · Recruiting
Azienda Ospedaliero Universitaria Careggi
Florence, Italy · Recruiting
Ospedale San Martino
Genova, Italy · Recruiting
Istituto Tumori della Romagna IRST IRCCS
Meldola, Italy · Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore
Milan, Italy · Recruiting
IEO Istituto Europeo di Oncologia
Milan, Italy · Recruiting
IRCCS Ospedale San Raffaele
Milan, Italy · Recruiting
Ospedale ASST Fatebenefratelli Sacco
Milan, Italy · Recruiting
ULSS 3 Veneto
Mirano, Italy · Recruiting
Azienda Ospedaliero-Universitaria
Modena, Italy · Recruiting
Azienda Ospedaliero-Universitaria Federico II
Naples, Italy · Recruiting
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Italy · Recruiting
Ospedale Maggiore della Carità
Novara, Italy · Recruiting
IOV Istituto Oncologico Veneto IRCCS
Padova, Italy · Recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy · Recruiting
IRCCS - ICS Maugeri
Pavia, Italy · Recruiting
Clinica Ospedaliero - Universitaria Policlinico Umberto I
Roma, Italy · Recruiting
Policlinico Universitario Campus Bio-Medico
Roma, Italy · Recruiting
Policlinico Universitario Fondazione Agostino Gemelli
Roma, Italy · Recruiting
Istituto Clinico Humanitas
Rozzano, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.